At the completion of this activity, the participant will be able to:
1. Describe driver mutations and the importance of molecular testing in patients with non-small cell lung cancer (NSCLC)
2. Review current literature and guidelines supporting targeted therapies for MET exon 14 skipping mutations and RET rearrangements
3. Discuss medication dosing, safety, and monitoring for MET and RET targeted therapies
4. Identify alterations in ERBB2/HER2 as an evolving target for advanced NSCLC

Session date: 
11/16/2020 - 12:00pm to 1:00pm EST
Location: 
Zoom: https://zoom.us/j/95179902145
Dial: 646 558 8656 or 301 715 8592
Meeting ID: 951 7990 2145
Passcode: 823482
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Please login or register to take this course.